Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma

NCT07706985 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

566

Enrollment

OTHER

Sponsor class

Conditions

Nasopharyngeal Carcinoma (NPC)

Interventions

DRUG: Toripalimab combined with Nimotuzumab
DRUG: Nimotuzumab

Sponsor

Sun Yat-sen University

Collaborators

[object Object]